Literature DB >> 11967646

How common are complications of Parkinson's disease?

Anette Schrag1, Yoav Ben-Shlomo, Niall Quinn.   

Abstract

BACKGROUND: Parkinson's disease (PD) can be associated with a wide range of complications of advancing disease and treatment. However, it is unclear how often these occur in the overall population of patients with PD.
OBJECTIVE: To assess the prevalence of disease and treatment complications and their clinical correlates in a community-based sample of 124 patients with PD.
RESULTS: Average current age was 72 (SD 10.9) and mean disease duration 6 (SD 4.3) years. Falls with postural instability and other axial features were among the most common complications of advancing disease in this population (64 %). Motor fluctuations and dyskinesias affected approximately 30 and 20 % of the overall sample respectively, and changes in mental state such as dementia, depression and hallucinations each affected approximately one fifth of patients. Symptoms of autonomic nervous system dysfunction occurred in the great majority of patients, but were not associated with greater disease severity, disease duration or overall disability.
CONCLUSION: In contrast to clinic-based samples, the most frequently occurring complications of PD in this community-based sample were axial features such as postural instability with falls. These factors should be more taken into account in the allocation of health care resources and the treatment of symptoms of patients with PD in the community.

Entities:  

Mesh:

Year:  2002        PMID: 11967646     DOI: 10.1007/s004150200032

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

Review 1.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

2.  Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease.

Authors:  Stina Bladh; Maria H Nilsson; Gun-Marie Hariz; Albert Westergren; Jeremy Hobart; Peter Hagell
Journal:  J Neurol       Date:  2011-09-29       Impact factor: 4.849

Review 3.  Use of a physiological profile to document motor impairment in ageing and in clinical groups.

Authors:  S R Lord; K Delbaere; S C Gandevia
Journal:  J Physiol       Date:  2015-12-07       Impact factor: 5.182

Review 4.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

Review 5.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

6.  Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2012-07-19

7.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors:  Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

Review 8.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 9.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

10.  Problem solving therapy for the treatment of depression for a patient with Parkinson's disease and mild cognitive impairment: a case study.

Authors:  R Scott Mackin; Patricia Areán; Alexandra Elite-Marcandonatou
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.